

Revance Therapeutics, Inc.  
Form 8-K  
June 03, 2015

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**  
**of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): June 3, 2015**

**REVANCE THERAPEUTICS, INC.**

**(Exact name of registrant as specified in its charter)**

**DELAWARE**  
**(State of**

**incorporation)**

**001-36297**  
**(Commission**

**File No.)**  
**Revance Therapeutics, Inc.**

**75-0551645**  
**(IRS Employer**

**Identification No.)**

Edgar Filing: Revance Therapeutics, Inc. - Form 8-K

**7555 Gateway Boulevard**

**Newark, California 94560**

**(Address of principal executive offices and zip code)**

**Registrant's telephone number, including area code: (510) 742-3400**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**ITEM 8.01 OTHER EVENTS.**

On June 3, 2015, Revance Therapeutics, Inc. issued a press release announcing the completion of an open-label study for its botulinum toxin product candidate, RT001, and its plans to initiate two clinical trials for RT001 in the second half of 2015.

The full text of the press release is attached hereto as Exhibit 99.1 and is hereby incorporated by reference.

**ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.**

**(d) Exhibits.**

<b>Number</b>	<b>Description</b>
99.1	Press Release dated June 3, 2015

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: June 3, 2015

Revance Therapeutics, Inc.

By: /s/ Lauren P. Silvernail

Lauren P. Silvernail

Executive Vice President, Corporate Development

and Chief Financial Officer

**EXHIBIT INDEX**

<b>Number</b>	<b>Description</b>
99.1	Press Release dated June 3, 2015